Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
Current Protocols in Protein Science|February 3, 2015
Ligand-directed profiling of organelles with internalizing phage librariesAndrey S Dobroff, Roberto Rangel, Liliana Guzman-Roja, et al.Cancer Research|September 19, 2012
Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxinRussell R Braeuer, Maya Zigler, Takafumi Kamiya, et al.The Journal of Biological Chemistry|August 26, 2009
Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasisVladislava O Melnikova, Krishnakumar Balasubramanian, Gabriel J Villares, et al.Proceedings of the National Academy of Sciences of the United States of America|March 13, 2015
Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptorsJami Mandelin, Marina Cardó-Vila, Wouter H P Driessen, et al.Plos One|June 12, 2008
Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activitiesLuciano Polonelli, José Pontón, Natalia Elguezabal, et al.The Journal of Biological Chemistry|February 16, 2012
β-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanomaDenise C Arruda, Luana C P Santos, Filipe M Melo, et al.Translational Oncology|August 7, 2010
Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma CellsAndrey S Dobroff, Elaine G Rodrigues, Maria A Juliano, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|January 17, 2016
Ligand-targeted theranostic nanomedicines against cancerVirginia J Yao, Sara D'Angelo, Kimberly S Butler, et al.Scientific Reports|June 28, 2017
Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo graftingDaniela I Staquicini, Roberto Rangel, Liliana Guzman-Rojas, et al.Elife|July 5, 2022
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trialMontaser F Shaheen, Julie Y Tse, Ethan S Sokol, et al.Pageof 3